Market Place
Sourcing Support
Arcturus Receives FDA Clearance for H5N1 Flu Vaccine Trial
11 Nov 2024 //
BUSINESSWIRE
Arcturus Therapeutics Q3 2024 Results & Pipeline Progress Update
07 Nov 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Report Q3 Results on Nov 7, 2024
31 Oct 2024 //
BUSINESSWIRE
Japan Approves CSL And Arcturus` Updated COVID-19 Vaccine For JN.1 Strain
13 Sep 2024 //
BUSINESSWIRE
Arcturus Therapeutics Gets FDA Clearance for ARCT-032 for Cystic Fibrosis
03 Sep 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
27 Aug 2024 //
BUSINESSWIRE
Arcturus Therapeutics Announces Q2 2024 Update And Pipeline Progress
05 Aug 2024 //
BUSINESSWIRE
Arcturus To Present At Canaccord Genuity Growth Conference
01 Aug 2024 //
BUSINESSWIRE
Arcturus To Report Q2 Results On August 5
18 Jul 2024 //
BUSINESSWIRE
Arcturus Updates OTC Deficiency And Cystic Fibrosis Programs
01 Jul 2024 //
BUSINESSWIRE
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
20 Jun 2024 //
BUSINESSWIRE
Arcturus Shows New CF Clinical Data At ECFC 2024
07 Jun 2024 //
BUSINESSWIRE
Arcturus teases data from small trial of inhalable cystic fibrosis mRNA therapy
29 May 2024 //
ENDPTS
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
28 May 2024 //
BUSINESSWIRE
Nature Comms: CSL, Arcturus COVID-19 Vaccine Efficacy, Tolerability
20 May 2024 //
PR NEWSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
15 May 2024 //
BUSINESSWIRE
Arcturus Therapeutics: Q1 2024 Financial Update, Pipeline Progress
08 May 2024 //
BUSINESSWIRE
Arcturus To Report Q1 2024 Results, Corporate Update on May 8
25 Apr 2024 //
BUSINESSWIRE
Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine
22 Mar 2024 //
ENDPTS
Arcturus Announces Fourth Quarter and Fiscal Year 2023 Financial Progress
07 Mar 2024 //
BUSINESSWIRE
Arcturus to Present at the Barclays 26th Annual Global Healthcare Conference
26 Feb 2024 //
BUSINESSWIRE
Arcturus Receives Orphan Medicinal Product Designation from the EC for ARCT-032
22 Feb 2024 //
BUSINESSWIRE
Arcturus to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
BUSINESSWIRE
PassPort Technologies Commences Collaborative Research with Arcturus
05 Jan 2024 //
PR NEWSWIRE
Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
04 Dec 2023 //
BUSINESSWIRE
Arcturus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Dec 2023 //
BUSINESSWIRE
CSL and Arcturus Therapeutics’ ARCT-154 Approved for COVID in Adults
28 Nov 2023 //
BUSINESSWIRE
Arcturus Receives Orphan Drug Designation from FDA for ARCT-032
27 Nov 2023 //
BUSINESSWIRE
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
14 Nov 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Report Third Quarter Financial Results
25 Oct 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
23 Oct 2023 //
BUSINESSWIRE
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS
04 Oct 2023 //
BUSINESSWIRE
Arcturus sa-mRNA COVID boosters induce immune response in ph. 2
19 Sep 2023 //
FIERCE BIOTECH
Study Shows sa-mRNA Vaccines Offer Robust Protection Against COVID-19 Variants
19 Sep 2023 //
BUSINESSWIRE
Arcturus and CSL Announce EMA Validates MAA for ARCT-154
05 Sep 2023 //
BUSINESSWIRE
Arcturus, ARCALIS Awarded $115M in Grants from the Japanese Government
23 Aug 2023 //
CONTRACT PHARMA
Arcturus Therapeutics to Attend Upcoming Investor Conferences
17 Aug 2023 //
BUSINESSWIRE
Japan awarded $115M to Arcturus JV to boost mRNA manufacturing
15 Aug 2023 //
FIERCE PHARMA
Arcturus Announces Second Quarter 2023 Financial Update and Pipeline Progress
07 Aug 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results
24 Jul 2023 //
BUSINESSWIRE
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810
01 Jun 2023 //
BUSINESSWIRE
Arcturus Therapeutics Announces 1Q 2023 Financial Update and Pipeline Progress
09 May 2023 //
BUSINESSWIRE
Arcturus to Report First Quarter Financial Results and Provide Corporate
26 Apr 2023 //
BUSINESSWIRE
Arcturus Announces Fourth Quarter 2022 Financial Update
28 Mar 2023 //
BUSINESSWIRE
Arcturus to Report Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
06 Feb 2023 //
BUSINESSWIRE
Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval
31 Jan 2023 //
BUSINESSWIRE
Arcturus to Present at the 41st Annual J.P. Morgan Healthcare Conference
19 Dec 2022 //
BUSINESSWIRE
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
13 Dec 2022 //
BUSINESSWIRE
CSL Announces Closing of Collaboration and Licensing Agreement with Arcturus
12 Dec 2022 //
PRNEWSWIRE
Arcturus Therapeutics Announces 3Q 2022 Financial Update and Pipeline Progress
09 Nov 2022 //
BUSINESSWIRE
Arcturus to Present at the Following Investor Conferences in November
07 Nov 2022 //
BUSINESSWIRE
CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal
03 Nov 2022 //
BIOSPACE
CSL Enters Licensing Agreement with Arcturus for Next Generation mRNA Vaccine
01 Nov 2022 //
PRNEWSWIRE
Arcturus Announces Collaboration with CSL to Develop and Commercialize
01 Nov 2022 //
BUSINESSWIRE
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results
26 Oct 2022 //
PRESS RELEASE
Arcturus Therapeutics to Attend the Following Investor Conferences
01 Sep 2022 //
BUSINESSWIRE
Arcturus Reports Durability Data Against Omicron Variants
18 Aug 2022 //
BUSINESSWIRE
